TTR and amyloidosis: A CRISPR–Cas9 in vivo gene editing approach for transthyretin amyloidosis is also being investigated in a clinical trial (funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051) [16].